Although top pharmaceutical companies are suffering from poor performance due to COVID-19, their research and development (R&D) costs are aggressively increasing. Newsmp compiled the ordinary R&D cost of five top pharmaceutical companies, including Yuhan Pharmaceuticals, GC Pharma, Chong Kun Dang Ph

The Statin+Ezetimibe combination market is pouring out a blockbuster.According to IQVIA, the Statin+Ezetimibe combination market expanded to KRW 330 billion last year with 20% growth despite the COVID-19.As a result, large-scale products that record more than KRW 10 billion per year have emerged. Th

The number of patients treated for ischemic heart disease has increased 4.1% annually over the past five years to more than 940,000 people.The total medical expenses for health insurance increased at a faster rate, reaching KRW 1.6511 trillion. ‘Ischemic heart disease’ refers to a disease caused by

Last year, the export performance of top pharmaceutical companies decreased notably in the aftermath of COVID-19.The pharmaceutical sector enjoyed a boom by recording a surplus for the first time in the second half of the year, but as demand was concentrated on diagnostic reagents and vaccines, othe

As the advent of the precision medicine era with the development of genome analysis evolves, the weight of Global Big Pharma is rapidly shifting from chronic diseases to anticancer drugs.Global Big Pharma also fell into a slump in the aftermath of COVID-19 but remained strong in the anticancer drug

Hypertension + hyperlipidemia combination drug market is gradually shifting its focus to the triple-drug combinations.According to the UBIST, the market for hypertension + hyperlipidemia combination drugs reached about KRW 33 billion last year, more than doubled from 2019.AmosartanQ (Hanmi Pharmaceu

Pharmaceutical exports continued to grow nearly 80% in January.January’s exports of medicinal and pharmaceutical products (SITC 54) reached USD 752.51 million, up 79.9% YoY, the Korea International Trade Association said.With a growth rate exceeding 50% for nine consecutive months since April of las

MSD Keytruda is solidifying its monopoly in the immuno-oncology market.Keytruda accounted for half of the immuno-oncology market, according to a report compiled by Newsmp on major global Big Pharma. Keytruda’s annual sales of last year amounted to KRW 16 trillion, up 29.7% from 2019. In particular,

In the fourth quarter of last year, the third pandemic of COVID-19 began in South Korea as well as in the United States and Europe, but it was found that global Big Pharma continued to grow.Global Big Pharma, which started to rebound in 3Q after suffering a slump until the first half of the year, ex

The share of imported products in pharmaceuticals is approaching the 35% level.According to the Statistics Korea’s 2020 manufacturing domestic supply index, the annual domestic supply index of pharmaceuticals last year was 131.9 (based on 100 in 2015), exceeding 130 for the first time since 2015.Sta

The aspirin + clopidogrel combination market started to wither before it even bloomed.According to UBIST, the combined prescription amount of aspirin + clopidogrel complex drugs, which reached KRW 40 billion in 2019, has decreased significantly to KRW 35 billion last year.All of the large products r

As the number of confirmed cases of coronavirus increased significantly, the number of pharmacies visited by confirmed people in Seoul also rose sharply in January.The Seoul Pharmaceutical Association (Chairman Dong-ju Han) announced that confirmed people visited 2,779 pharmacies as of 18:00 on Janu

Eisai’s Equfina film-coated Tab. 50mg (ingredient Safinamide), adjuvant therapy for patients with idiopathic Parkinson’s disease, and Santen’s Eybelis eye drops 0.002% (ingredient: Omidenepag Isopropyl) would be reimbursed from this month.The insurance coverage will take effect as of February 1, the

Japanese pharmaceutical companies had been sluggish in the outpatient prescription market last year.According to UBIST, the combined amount of over-the-counter sales for nine Japanese pharmaceutical companies in 2020 was KRW 675.2 billion, down 1.56% from 2019.In particular, large companies showed p

Dukaro (Boryung Pharmaceutical) posted the best performance among new drugs that entered the outpatient prescription market last year.According to UBIST, unlike previous years, no more royal roaders reached KRW 10 billion blockbusters in the first year of its launch last year.Among them, Dukaro made

Exports of diagnostic reagents exceeded $300 million in December last year. Annual exports also surpassed $2 billion.According to the Korea Customs Service, exports of diagnostic reagents (HS3802) reached $310.9 million in December, up 941.2% YoY, surpassing $300 million for the first time. This is

The Korean Pharmaceutical Association (Chairman Dae-up Kim) has warned its members about selling Chloroquine, Dexamethasone, and Ivermectin without caution.On the 4th, the Ministry of Food and Drug Safety (MFDS) asked the Pharmaceutical Association to comply with the permission to sell those drugs w

Eleven pharmaceutical and bio firms announced a total of KRW 2 trillion worth of new facility investment plans last year. (excluding corrective disclosure)Among them, Samsung Biologics said that it would invest KRW 1.74 trillion to add a fourth plant at Songdo, Incheon, accounting for an absolute pr

Animal drug experts still warn that humans should not take the veterinary anti-parasite drug Ivermectin, while the studies have shown that it has lowered the fatality of COVID-19.British Daily Mail Online reported on the 5th that Ivermectin had a significant effect on removing the COVID-19 virus fro

In the aftermath of COVID-19 last year, the annual consumer price index (CPI) rose only 0.5%, while the pharmaceutical CPI also remained at 0.43p, 0.4% from 102.92 to 103.35 (as of 100 in 2015).Most of the pharmaceutical CPIs stayed unchanged, but analgesics alone rose more than 5%.According to Stat